A plain-English tracker of what's actually legal in peptide therapy right now, and where to get it properly.

Updated — Oct 17, 2026

Tracker / About

About

Who we are and how we check facts

OnlineDrugs.com is a plain-English tracker of what's legal in peptide therapy and GLP-1 medications in the US, and where to get them properly.

Who runs this site

OnlineDrugs.com has had the same owner for 25 years. The tracker is written and maintained by a small team whose background is behavioral health technology and operations.

We're not a pharmacy, a clinic, or a law firm. We don't sell, prescribe, or ship any medication.

How we source

How we keep it current

The date at the top of every page changes when we update the content. Each status page also says when its short answer was last checked, and the docket dates every regulatory step. When the FDA acts, we update the affected pages and email subscribers.

Medical review

When a page has been reviewed by a licensed clinician, it says so at the top and names the reviewer, along with what the review covered. Pages without that note haven't been clinically reviewed.

How we make money

Some provider listings on this site are referral links. If you sign up through one, we may earn a fee, at no cost to you. Each listing is labeled.

Referral relationships don't change what we report about legal status. We list the same vetting checklist for every provider, including the ones we link to. We aren't affiliated with the FDA, any pharmacy, or any provider's medical practice, and we never link to or rank research-use-only sellers.

Corrections

If we got something wrong, tell us. Use the form below and choose “Report a correction.” We fix errors promptly, and we note significant corrections on the page they affect.

Not medical or legal advice

This site explains regulatory status. It can't tell you whether a treatment is right for you. Confirm current status and suitability with a licensed healthcare provider before making a decision.

Get an email when the FDA rules.

One short email when the FDA proposes or finalizes anything on peptide compounding, or when the GLP-1 rules change. Nothing else.

Free. Every email includes an unsubscribe link, and we don't sell or share your address.